Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.26-0.39 (-5.10%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.65
Open7.76
Bid7.22 x 2200
Ask7.25 x 3200
Day's Range7.18 - 7.90
52 Week Range0.28 - 18.77
Volume13,820,815
Avg. Volume32,690,101
Market Cap1.439B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 04, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.90
  • GlobeNewswire

    Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

    MALVERN, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States. The FDA plans to identify the specific deficiencies that are th

  • Motley Fool

    3 Small-Cap COVID Stocks With Huge Upside

    While large-cap stocks are usually safer, small-cap stocks are often way more exciting. If you own the right small cap, you can make a lot of money as your company becomes the large cap of tomorrow. This panel of Fool.com contributors has three small-cap COVID-19 stock ideas for intrepid investors.

  • InvestorPlace

    Think Twice Before You Roll the Dice on Ocugen Stock

    As I expected, traders have kept selling Ocugen (NASDAQ:OCGN) stock in the wake of the recent news about the company. The biotech firm — which is trying to bring Covaxin, a Covid-19 vaccine, to the U.S. and Canada — surged a few weeks back. Last month, traders bid up OCGN stock in anticipation of an expected emergency use listing {EUL} for Covaxin from the World Health Organization (WHO). Source: shutterstock.com/PhotobyTawat As a result, the shares went from $9 to as much as $17.65 per share. B

Advertisement
Advertisement